Email Updates

You are here

Webinar & Meeting Reports

  • August 4, 2020

    Right now, COVID-19 is wreaking havoc on access to HIV treatment and prevention across the continent. In a matter of days, African countries will reach a grim milestone: the number of COVID-19 cases will surge past 1 million. Many clinics where adults and children get lifesaving HIV treatment have simply shuttered. Medicine supply chains have been disrupted, resulting in life-threatening shortages of drugs.

  • July 30, 2020

    On July 30, FP2020 and AVAC had a webinar on sexual and reproductive health (SRH) integration: One Year After ECHO: Integration in the Time of COVID. This discussion focused on gains made in the year following the ECHO trial results; how COVID-19 has had an impact on HIV and SRH services and efforts to integrate them; and what the future of HIV/SRH integration can and should look like.

  • July 29, 2020

    On July 29, AVAC held a webinar Understanding the EMA Opinion: Next Steps for Dapivirine Vaginal Ring for advocates to learn about next steps on the regulatory process and implications for rollout from advocates, International Partnership for Microbicides (IPM) and the WHO.

  • July 16, 2020

    The HIV Prevention Trials Network (HPTN) held a community webinar, on July 16, to present the primary results of HPTN 083, a global randomized, controlled, double-blinded study that compared the safety and efficacy of long-acting injectable cabotegravir (CAB LA) to daily oral tenofovir/emtricitabine (TDF/FTC) (Truvada) for pre-exposure prophylaxis (PrEP).

  • July 6, 2020 to October 23, 2020

    An alliance of global key population-led networks, networks of people living with HIV, treatment activists, and our supporters, has formed to organize an alternative international community-led online event. Titled, HIV2020: Community Reclaiming the Global Response, the event is scheduled to take place on Zoom from July through October of 2020.

  • July 1, 2020 to July 10, 2020

    In early July, the world’s largest gathering on HIV/AIDS went virtual for the first time. AIDS 2020:Virtual, the 23rd edition of the International AIDS Conference, offered the latest scientific breakthroughs on HIV, opportunities for advocates to come together to sharpen their agenda and new to this year, a special day-long meeting devoted to COVID-19.

  • June 22, 2020 to August 28, 2020

    This 10-week interactive and online course will help researchers and clinical trial stakeholder to apply the Good Participatory Practice (GPP) Guidelines in their unique settings. In this unprecedented time, sustaining effective partnerships is more crucial than ever before. This course provides a personalized learning experience, global knowledge, tools to advance GPP implementation in diverse contexts and access to GPP experts and professional networks. For more information, send an email to gpponlinecourse@avac.org.

  • June 9, 2020

    The COVID-19 pandemic has accelerated the research process. Sponsors, researchers, ethics committee members and other stakeholders are moving faster than ever to move effective products through the research pipeline. The pace of the research is also changing how stakeholder engagement is conducted. On Tuesday, June 9, speakers discussed the experience of conducting stakeholder engagement during the Ebola crisis in West Africa. They also explored some of the ethical challenges to conducting research in a public health emergency.

  • June 1, 2020 to October 30, 2020

    The HIV2020 Conference has been reimagined as a series of virtual convenings that will take place June through October of this year.

  • May 22, 2020

    On Friday, May 22, the HIV Prevention Trials Network (HPTN) held a community webinar to discuss the preliminary results of HPTN 083, a global randomized, controlled, double-blinded study that compared the safety and efficacy of long-acting injectable cabotegravir (CAB LA) to daily oral tenofovir/emtricitabine (TDF/FTC) (Truvada) for pre-exposure prophylaxis (PrEP). The study showed that CAB LA lowered HIV incidence among cisgender men and transgender women who have sex with men.

Pages